Back

TFEB and TFE3 have cell-type specific expression in the brain and divergent roles in neurons

McGuinness, W.; Ryan, B. J.; Guardado, C. L.; Carling, P.; Vallin, B.; Caiazza, M. C.; Heon-Roberts, R.; Kilfeather, P.; Wantling, J.; Hoffmann, J.; Aird, D.; Lofstromm, K.; Zhang, M.; Cowley, S. A.; Hirst, W. D.; Wade-Martins, R.

2025-04-23 cell biology
10.1101/2025.04.22.649949 bioRxiv
Show abstract

Lysosomal dysfunction occurs in many neurodegenerative diseases, including Parkinsons disease, and activating TFEB to enhance lysosomal biogenesis is a promising therapeutic strategy. To understand TFEB physiology in cells of the brain, we characterised TFEB expression using iPSC-derived models, and transcriptomic analysis of human and mouse brain tissue. Surprisingly, TFEB expression at the RNA and protein level was restricted to glia, whereas the related transcription factor, TFE3, was expressed ubiquitously. We identified HDAC1/2/3 as transcriptional repressors of neuronal TFEB and found the brain-penetrant HDAC inhibitor ACY-738 derepressed TFEB expression and enhanced TFE3 nuclear translocation in iPSC-dopaminergic neurons (iPSC-DaNs). We delineated the role of each transcription factor by genetic manipulation in iPSC-DaNs to reveal divergent roles in which TFEB activates mitochondrial biogenesis, whereas TFE3 enhances lysosomal biogenesis. Finally, we show TFE3 activation corrects the lysosomal dysfunction associated with GBA-N370S and SNCA-Triplication mutations in Parkinsons patient-derived iPSC-DaNs, demonstrating therapeutic utility in neurodegeneration.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.